Zoetis (NYSE:ZTS) Announces Earnings Results, Beats Expectations By $0.07 EPS

Zoetis (NYSE:ZTS) announced its quarterly earnings results on Tuesday. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07, Briefing.com reports. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The firm had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. During the same period in the previous year, the company earned $1.41 earnings per share. Zoetis’s quarterly revenue was up 8.3% compared to the same quarter last year. Zoetis updated its FY24 guidance to $5.78-5.88 EPS and its FY 2024 guidance to 5.780-5.880 EPS.

Zoetis Trading Down 0.2 %

Shares of Zoetis stock traded down $0.39 during trading hours on Wednesday, hitting $184.90. The company’s stock had a trading volume of 2,097,111 shares, compared to its average volume of 2,803,766. Zoetis has a 1-year low of $144.80 and a 1-year high of $201.92. The business has a fifty day moving average of $175.81 and a 200 day moving average of $175.36. The company has a market capitalization of $84.37 billion, a PE ratio of 35.70, a P/E/G ratio of 2.80 and a beta of 0.86. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 4th. Stockholders of record on Thursday, July 18th will be given a $0.432 dividend. This represents a $1.73 annualized dividend and a dividend yield of 0.93%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s payout ratio is currently 33.33%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ZTS. Barclays reduced their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 23rd. HSBC reduced their target price on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. BTIG Research began coverage on shares of Zoetis in a report on Thursday, July 25th. They issued a “buy” rating and a $220.00 target price for the company. Piper Sandler reiterated an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Finally, Stifel Nicolaus boosted their price target on shares of Zoetis from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Monday. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $214.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.